KCI등재
SCIE
Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study
저자
Soon Kyu Lee (Division of Hepatology, Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea) ; Sung Won Lee (The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea) ; Hae Lim Lee (The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea) ; Hee Yeon Kim (The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea) ; Chang Wook Kim (The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea) ; Do Seon Song (The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea) ; U Im Chang (The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea) ; Jin Mo Yang (The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea) ; Sun Hong Yoo (Division of Hepatology, Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea) ; Jung Hyun Kwon (Division of Hepatology, Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea) ; Soon Woo Nam (Division of Hepatology, Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea) ; Seok-Hwan Kim (The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea) ; Myeong Jun Song (The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea) ; Jaejun Lee (The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea) ; Hyun Yang (The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea) ; Si Hyun Bae (The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea) ; Ji Won Han (The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea) ; Heechul Nam (The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea) ; Pil Soo Sung (The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea) ; Jeong Won Jang (The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea) ; Jong Young Choi (The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea) ; Seung Kew Yoon (The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea) 연구자관계분석
발행기관
학술지명
The Korean Journal of Internal Medicine(The Korean Journal of Internal Medicine)
권호사항
발행연도
2022
작성언어
English
주제어
등재정보
KCI등재,SCIE
자료형태
학술저널
발행기관 URL
수록면
1167-1175(9쪽)
DOI식별코드
제공처
Background/Aims : To evaluate the efficacy and safety of ledipasvir/sofosbuvir (LDV/SOF) therapy in hepatitis C virus (HCV)-infected Korean patients in a real clinical setting.
Methods: A total of 273 patients who received LDV/SOF therapy between May 2016 and February 2021 were consecutively enrolled and analyzed. A per-protocol analysis was performed to evaluate the virologic response.
Results: Seventy-five percent were infected with genotype 1, and 25% were infected with genotype 2. A hundred eightyone (66.3%) patients had chronic hepatitis, 74 (27.1%) had compensated cirrhosis, eight (2.9%) had decompensated cirrhosis, and 10 (3.7%) had undergone liver transplantation. Undetectable HCV RNA at week 4 was achieved in 90.2% (231/256) of patients, 99.2% (250/252) achieved the end of treatment response, and 98.1% (202/206) achieved sustained virologic response at 12 weeks post-treatment (SVR12). According to liver function, the SVR12 rates were 99.3% (135/136) in chronic hepatitis, 96.4% (53/55) in compensated cirrhosis, and 100% (6/6) in decompensated cirrhosis. The SVR12 rates according to the genotype were 98.2% (167/170) for genotype 1 and 97.2% (35/36) for genotype 2. An 8-week LDV/SOF treatment in treatment-naïve chronic hepatitis patients with HCV RNA < 6,000,000 IU/mL at baseline resulted in 100% (23/23) SVR12 rates. Overall, LDV/SOF was tolerated well, with a 0.7% (2/273) discontinuation rate due to adverse events that were unrelated to LDV/SOF.
Conclusions: LDV/SOF is effective and safe for treating HCV-infected Korean patients with high SVR12 rates.
서지정보 내보내기(Export)
닫기소장기관 정보
닫기권호소장정보
닫기오류접수
닫기오류 접수 확인
닫기음성서비스 신청
닫기음성서비스 신청 확인
닫기이용약관
닫기학술연구정보서비스 이용약관 (2017년 1월 1일 ~ 현재 적용)
학술연구정보서비스(이하 RISS)는 정보주체의 자유와 권리 보호를 위해 「개인정보 보호법」 및 관계 법령이 정한 바를 준수하여, 적법하게 개인정보를 처리하고 안전하게 관리하고 있습니다. 이에 「개인정보 보호법」 제30조에 따라 정보주체에게 개인정보 처리에 관한 절차 및 기준을 안내하고, 이와 관련한 고충을 신속하고 원활하게 처리할 수 있도록 하기 위하여 다음과 같이 개인정보 처리방침을 수립·공개합니다.
주요 개인정보 처리 표시(라벨링)
목 차
3년
또는 회원탈퇴시까지5년
(「전자상거래 등에서의 소비자보호에 관한3년
(「전자상거래 등에서의 소비자보호에 관한2년
이상(개인정보보호위원회 : 개인정보의 안전성 확보조치 기준)개인정보파일의 명칭 | 운영근거 / 처리목적 | 개인정보파일에 기록되는 개인정보의 항목 | 보유기간 | |
---|---|---|---|---|
학술연구정보서비스 이용자 가입정보 파일 | 한국교육학술정보원법 | 필수 | ID, 비밀번호, 성명, 생년월일, 신분(직업구분), 이메일, 소속분야, 웹진메일 수신동의 여부 | 3년 또는 탈퇴시 |
선택 | 소속기관명, 소속도서관명, 학과/부서명, 학번/직원번호, 휴대전화, 주소 |
구분 | 담당자 | 연락처 |
---|---|---|
KERIS 개인정보 보호책임자 | 정보보호본부 김태우 | - 이메일 : lsy@keris.or.kr - 전화번호 : 053-714-0439 - 팩스번호 : 053-714-0195 |
KERIS 개인정보 보호담당자 | 개인정보보호부 이상엽 | |
RISS 개인정보 보호책임자 | 대학학술본부 장금연 | - 이메일 : giltizen@keris.or.kr - 전화번호 : 053-714-0149 - 팩스번호 : 053-714-0194 |
RISS 개인정보 보호담당자 | 학술진흥부 길원진 |
자동로그아웃 안내
닫기인증오류 안내
닫기귀하께서는 휴면계정 전환 후 1년동안 회원정보 수집 및 이용에 대한
재동의를 하지 않으신 관계로 개인정보가 삭제되었습니다.
(참조 : RISS 이용약관 및 개인정보처리방침)
신규회원으로 가입하여 이용 부탁 드리며, 추가 문의는 고객센터로 연락 바랍니다.
- 기존 아이디 재사용 불가
휴면계정 안내
RISS는 [표준개인정보 보호지침]에 따라 2년을 주기로 개인정보 수집·이용에 관하여 (재)동의를 받고 있으며, (재)동의를 하지 않을 경우, 휴면계정으로 전환됩니다.
(※ 휴면계정은 원문이용 및 복사/대출 서비스를 이용할 수 없습니다.)
휴면계정으로 전환된 후 1년간 회원정보 수집·이용에 대한 재동의를 하지 않을 경우, RISS에서 자동탈퇴 및 개인정보가 삭제처리 됩니다.
고객센터 1599-3122
ARS번호+1번(회원가입 및 정보수정)